Last reviewed · How we verify
NCT05011643
Exercise-induced Muscle Damage in Statin Users
trial testing Moderate-intensity exercise in Cardiovascular Diseases in 100 participants. Completed in 20 July 2018.
20 July 2018
Quick facts
| Lead sponsor | Radboud University Medical Center |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 29 May 2018 |
| Primary completion | 20 July 2018 |
| Estimated completion | 20 July 2018 |
| Sites | 1 location across Netherlands |
Drugs / interventions tested
- Moderate-intensity exercise
Conditions studied
- Cardiovascular Diseases — all drugs for Cardiovascular Diseases →
- HMG COA Reductase Inhibitor Adverse Reaction — all drugs for HMG COA Reductase Inhibitor Adverse Reaction →
- Muscle Damage — all drugs for Muscle Damage →
Sponsor
Radboud University Medical Center
Who can join
Adults 40 to 75, any sex, with Cardiovascular Diseases or HMG COA Reductase Inhibitor Adverse Reaction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Rationale: Combining statin treatment and physical activity is very effective for the prevention of cardiovascular diseases. Statins are well-tolerated by most patients, but may cause statin-associated muscle symptoms (SAMS) and elevated markers of skeletal muscle damage in some patients. Several studies have shown that statins augment increases in serum creatine kinase after eccentric or vigorous exercise. If statins also increase muscle damage markers after exercises of moderate intensity is unclear. Symptomatic statin users may be more susceptible to exercise-induced skeletal muscle injury, however, previous studies did not differentiate between symptomatic and asymptomatic statin users. Objective: To compare the impact of moderate-intensity exercise on muscle damage markers between symptomatic and asymptomatic statin users, and non-statin using controls. A secondary objective is to examine the association between leukocytes coenzyme Q10 levels and exercise-induced muscle damage and muscle complaints.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Prolonged Moderate-Intensity Exercise Does Not Increase Muscle Injury Markers in Symptomatic or Asymptomatic Statin Users.
Allard NAE, Janssen L, Lagerwaard B, Nuijten MAH, et al · · 2023 · cited 8× · PMID 37019582 · DOI 10.1016/j.jacc.2023.01.043 -
Mitochondrial complex III activity: from invasive muscle biopsies to patient-friendly buccal swab analysis.
Somers T, Allard NAE, Siddiqi S, Janssen MCM, et al · · 2023 · cited 1× · PMID 37316639 · DOI 10.1038/s41598-023-36741-w
Verify or expand the search:
- PubMed search for NCT05011643
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cardiovascular Diseases
Currently open trials in the same condition.
- NCT07442578 — Impact of Exercise Intensity on Cardiac Health in Young Adult Survivors of Childhood Cancer: The PULSE Trial · NA · active not recruiting
- NCT07426263 — Effectiveness of a Therapeutic Education Program on Female Sexuality in Women Attending Cardiac Rehabilitation. · NA · active not recruiting
- NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
- NCT07324278 — Hybrid Stroke Rehab With Mirror Priming · NA · recruiting
- NCT07286578 — A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Under · NA · recruiting
Other Radboud University Medical Center trials
Trials by the same sponsor.
- NCT07485569 — Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial · Phase 1 · not yet recruiting
- NCT07514325 — MR-guided Adaptive Stereotactic Radiotherapy for Endometrial Cancer · NA · not yet recruiting
- NCT07530263 — Deposition of Inhaled Liposomal Amphotericin B in Chronic Pulmonary Aspergillosis (CPA) · Phase 1 · not yet recruiting
- NCT07532577 — Intranasal Insulin to Prevent Intensive Care Unit Delirium · Phase 2, PHASE3 · not yet recruiting
- NCT07504172 — Real-world Effectiveness and Dosing Patterns of Tirzepatide in People With Obesity · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05011643 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Radboud University Medical Center
- Last refreshed: 27 August 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05011643.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing